Small Molecule Drug Conjugates (SMDCs) are emerging as a strategic pivot in targeted therapy: instead of relying solely on a “lock-and-key” interaction, they couple molecular precision with controlled delivery of a cytotoxic payload. In practice, an SMDC pairs a targeting scaffold with a linker and drug moiety, aiming to improve therapeutic index by concentrating potency where...